Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08FDX
|
|||
| Former ID |
DNCL002525
|
|||
| Drug Name |
MGCD265
|
|||
| Synonyms |
MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
MethylGene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H20FN5O2S2
|
|||
| Canonical SMILES |
CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F
|
|||
| InChI |
1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
|
|||
| InChIKey |
UFICVEHDQUKCEA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 875337-44-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
53786494, 57467996, 99437110, 103563466, 124757189, 125163993, 125313607, 125329950, 131480853, 136340177, 136367400, 136367877, 144116213, 152043932, 152258291, 160647130, 162011388, 162037559, 162158466, 162202667, 170559183, 174006596, 174531054, 176242979, 177748915, 180386843, 185990454, 188899575, 223592785, 223705039, 229580997, 242060283, 245344485, 249492384, 249820208, 252109880, 252215794
|
|||
| ChEBI ID |
CHEBI:91393
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein kinase (PK) | Target Info | Inhibitor | [2] |
| Tyrosine-protein kinase UFO (AXL) | Target Info | Modulator | [3] | |
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | VEGFA-VEGFR2 Pathway | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02544633) Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Company report (Mirati Therapeutics: formerly MethylGene) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.